Apollo Endosurgery, Inc.

DB:HQ8F Voorraadrapport

Marktkapitalisatie: €531.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Apollo Endosurgery Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Chas McKhann

Algemeen directeur

US$2.8m

Totale compensatie

Percentage CEO-salaris19.8%
Dienstverband CEO2.1yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn4.3yrs
Gemiddelde ambtstermijn bestuur5.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chas McKhann's beloning veranderd ten opzichte van Apollo Endosurgery's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2022US$3mUS$550k

-US$40m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$9mUS$375k

-US$25m

Compensatie versus markt: Chas's total compensation ($USD2.78M) is above average for companies of similar size in the German market ($USD886.27K).

Compensatie versus inkomsten: Chas's compensation has been consistent with company performance over the past year.

CEO

Chas McKhann (53 yo)

2.1yrs

Tenure

US$2,780,544

Compensatie

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Charles McKhann
CEO, President & Director2.1yrsUS$2.78m0.39%
€ 2.1m
Jeffrey Black
CFO, Secretary & Treasurer1.7yrsUS$1.34m0.18%
€ 951.6k
John Molesphini
Executive Vice President of Operations5yrsUS$662.23k0.079%
€ 422.7k
Sergey Kantsevoy
Co-Founder and Innovation Partnerno datageen gegevensgeen gegevens
Anthony Kalloo
Co-Founder and Innovation Partnerno datageen gegevensgeen gegevens
Robert Hawes
Co-Founder and Innovation Partnerno datageen gegevensgeen gegevens
Peter Cotton
Co-Founder and Innovation Partner18.3yrsgeen gegevensgeen gegevens
Christopher Gostout
Co-Founder & Chief Medical Officerno dataUS$1.16m0.062%
€ 331.3k
Sydney Chung
Co-Founder and Innovation Partnerno datageen gegevensgeen gegevens
Pankaj Pasricha
Co-Founder18.3yrsgeen gegevensgeen gegevens
John Gillings
Investor Relations Managerno datageen gegevensgeen gegevens
Brian Szymczak
Vice President of Legal & Compliance3.6yrsgeen gegevensgeen gegevens

4.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: HQ8F's management team is considered experienced (4.3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Charles McKhann
CEO, President & Director2.1yrsUS$2.78m0.39%
€ 2.1m
John Barr
Independent Chairman of the Board4.1yrsUS$193.24k0.051%
€ 273.8k
Julie Shimer
Independent Director4.9yrsUS$164.49k0.038%
€ 199.9k
Richard McGaughy
Independent Director11.3yrsUS$165.15kgeen gegevens
William McClellan
Independent Director8.9yrsUS$169.49k0.047%
€ 247.9k
Adrian Park
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Mark Talamini
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Santiago Horgan
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jay Redan
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Steve McCarus
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jeffrey Marks
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Pacitti
Independent Director5.4yrsUS$159.70k0.0067%
€ 35.7k

5.2yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: HQ8F's board of directors are considered experienced (5.2 years average tenure).